Literature DB >> 29084859

Cystic Fibrosis Airway Microbiome: Overturning the Old, Opening the Way for the New.

George A O'Toole1.   

Abstract

The genetic disease cystic fibrosis (CF) is associated with chronic airway infections that are a proximal cause of death in many patients with this affliction. Classic microbiology studies focusing on canonical pathogens resulted in the development of a common set of views regarding the nature of the airway infections associated with this disease, and these ideas have influenced everything from the way infections are treated to how clinical trials for new CF-targeted antibiotics are designed and the focus of CF-related research topics. Recent culture-independent studies have prompted us to rethink, and in some cases discard, some of these long-held views. In this piece, I argue that an updated view of the complicated chronic infections associated with CF, thanks in large part to culture-independent studies of sputum and bronchoalveolar lavage fluid samples, should be leveraged to develop new strategies to treat these recalcitrant infections.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  airway; cystic fibrosis; infection; microbiome; sputum

Mesh:

Substances:

Year:  2018        PMID: 29084859      PMCID: PMC5786703          DOI: 10.1128/JB.00561-17

Source DB:  PubMed          Journal:  J Bacteriol        ISSN: 0021-9193            Impact factor:   3.490


  76 in total

1.  True microbiota involved in chronic lung infection of cystic fibrosis patients found by culturing and 16S rRNA gene analysis.

Authors:  Vibeke B Rudkjøbing; Trine R Thomsen; Morten Alhede; Kasper N Kragh; Per H Nielsen; Ulla R Johansen; Michael Givskov; Niels Høiby; Thomas Bjarnsholt
Journal:  J Clin Microbiol       Date:  2011-10-19       Impact factor: 5.948

2.  Concordance between upper and lower airway microbiota in infants with cystic fibrosis.

Authors:  Sabine M P J Prevaes; Wouter A A de Steenhuijsen Piters; Karin M de Winter-de Groot; Hettie M Janssens; Gerdien A Tramper-Stranders; Mei Ling J N Chu; Harm A Tiddens; Mireille van Westreenen; Cornelis K van der Ent; Elisabeth A M Sanders; Debby Bogaert
Journal:  Eur Respir J       Date:  2017-03-29       Impact factor: 16.671

Review 3.  Treatment of pulmonary exacerbations in cystic fibrosis - could do better?

Authors:  Alan Smyth
Journal:  Paediatr Respir Rev       Date:  2016-06-15       Impact factor: 2.726

4.  Does the F508-CFTR mutation induce a proinflammatory response in human airway epithelial cells?

Authors:  Thomas H Hampton; Alicia E Ballok; Jennifer M Bomberger; Melanie R Rutkowski; Roxanna Barnaby; Bonita Coutermarsh; José R Conejo-Garcia; George A O'Toole; Bruce A Stanton
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-07-20       Impact factor: 5.464

5.  Direct sampling of cystic fibrosis lungs indicates that DNA-based analyses of upper-airway specimens can misrepresent lung microbiota.

Authors:  Amanda F Goddard; Benjamin J Staudinger; Scot E Dowd; Amruta Joshi-Datar; Randall D Wolcott; Moira L Aitken; Corinne L Fligner; Pradeep K Singh
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-07       Impact factor: 11.205

6.  Prevalence of streptococci and increased polymicrobial diversity associated with cystic fibrosis patient stability.

Authors:  L M Filkins; T H Hampton; A H Gifford; M J Gross; D A Hogan; M L Sogin; H G Morrison; B J Paster; G A O'Toole
Journal:  J Bacteriol       Date:  2012-06-29       Impact factor: 3.490

7.  Molecular analysis of changes in Pseudomonas aeruginosa load during treatment of a pulmonary exacerbation in cystic fibrosis.

Authors:  D W Reid; R Latham; I L Lamont; M Camara; L F Roddam
Journal:  J Cyst Fibros       Date:  2013-05-22       Impact factor: 5.482

Review 8.  Respiratory care of the hospitalized patient with cystic fibrosis.

Authors:  Thomas J Newton
Journal:  Respir Care       Date:  2009-06       Impact factor: 2.258

9.  Lung microbiota across age and disease stage in cystic fibrosis.

Authors:  Bryan Coburn; Pauline W Wang; Julio Diaz Caballero; Shawn T Clark; Vijaya Brahma; Sylva Donaldson; Yu Zhang; Anu Surendra; Yunchen Gong; D Elizabeth Tullis; Yvonne C W Yau; Valerie J Waters; David M Hwang; David S Guttman
Journal:  Sci Rep       Date:  2015-05-14       Impact factor: 4.379

10.  Rapid 16S rRNA next-generation sequencing of polymicrobial clinical samples for diagnosis of complex bacterial infections.

Authors:  Stephen J Salipante; Dhruba J Sengupta; Christopher Rosenthal; Gina Costa; Jessica Spangler; Elizabeth H Sims; Michael A Jacobs; Samuel I Miller; Daniel R Hoogestraat; Brad T Cookson; Connor McCoy; Frederick A Matsen; Jay Shendure; Clarence C Lee; Timothy T Harkins; Noah G Hoffman
Journal:  PLoS One       Date:  2013-05-29       Impact factor: 3.240

View more
  22 in total

1.  How adaptive immunity constrains the composition and fate of large bacterial populations.

Authors:  Madeleine Bonsma-Fisher; Dominique Soutière; Sidhartha Goyal
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-23       Impact factor: 11.205

2.  Pseudomonas aeruginosa Can Inhibit Growth of Streptococcal Species via Siderophore Production.

Authors:  Jessie E Scott; Kewei Li; Laura M Filkins; Bin Zhu; Sherry L Kuchma; Joseph D Schwartzman; George A O'Toole
Journal:  J Bacteriol       Date:  2019-03-26       Impact factor: 3.490

3.  Cooperativity between Stenotrophomonas maltophilia and Pseudomonas aeruginosa during Polymicrobial Airway Infections.

Authors:  Melissa S McDaniel; Trenton Schoeb; W Edward Swords
Journal:  Infect Immun       Date:  2020-03-23       Impact factor: 3.441

4.  Nontypeable Haemophilus influenzae Infection Impedes Pseudomonas aeruginosa Colonization and Persistence in Mouse Respiratory Tract.

Authors:  Natalie R Lindgren; Lea Novak; Benjamin C Hunt; Melissa S McDaniel; W Edward Swords
Journal:  Infect Immun       Date:  2021-11-15       Impact factor: 3.609

Review 5.  Accelerated Approval or Risk Reduction? How Response Biomarkers Advance Therapeutics through Clinical Trials in Cystic Fibrosis.

Authors:  N Mayer-Hamblett; D R VanDevanter
Journal:  Trends Mol Med       Date:  2020-08-28       Impact factor: 11.951

6.  Maintenance tobramycin primarily affects untargeted bacteria in the CF sputum microbiome.

Authors:  Maria T Nelson; Daniel J Wolter; Alexander Eng; Eli J Weiss; Anh T Vo; Mitchell J Brittnacher; Hillary S Hayden; Sumedha Ravishankar; Gilbert Bautista; Anina Ratjen; Marcella Blackledge; Sharon McNamara; Laura Nay; Cheryl Majors; Samuel I Miller; Elhanan Borenstein; Richard H Simon; John J LiPuma; Luke R Hoffman
Journal:  Thorax       Date:  2020-07-06       Impact factor: 9.139

7.  Allelic polymorphism shapes community function in evolving Pseudomonas aeruginosa populations.

Authors:  Sheyda Azimi; Aled E L Roberts; Shengyun Peng; Joshua S Weitz; Alan McNally; Samuel P Brown; Stephen P Diggle
Journal:  ISME J       Date:  2020-04-27       Impact factor: 10.302

Review 8.  Treatment of Pulmonary Disease of Cystic Fibrosis: A Comprehensive Review.

Authors:  Rosa María Girón Moreno; Marta García-Clemente; Layla Diab-Cáceres; Adrián Martínez-Vergara; Miguel Ángel Martínez-García; Rosa Mar Gómez-Punter
Journal:  Antibiotics (Basel)       Date:  2021-04-23

9.  Metabolic Modeling of Cystic Fibrosis Airway Communities Predicts Mechanisms of Pathogen Dominance.

Authors:  Michael A Henson; Giulia Orazi; Poonam Phalak; George A O'Toole
Journal:  mSystems       Date:  2019-04-23       Impact factor: 6.496

Review 10.  The Bactericidal Tandem Drug, AB569: How to Eradicate Antibiotic-Resistant Biofilm Pseudomonas aeruginosa in Multiple Disease Settings Including Cystic Fibrosis, Burns/Wounds and Urinary Tract Infections.

Authors:  Daniel J Hassett; Rhett A Kovall; Michael J Schurr; Nalinikanth Kotagiri; Harshita Kumari; Latha Satish
Journal:  Front Microbiol       Date:  2021-06-17       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.